Header Logo

Connection

CHRISTIE BALLANTYNE to Biomarkers

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Biomarkers.
CHRISTIE BALLANTYNE
Connection Strength
7.134
Biomarkers
  1. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study. Clin Chem. 2013 Dec; 59(12):1802-10.
    View in: PubMed
    Score: 0.210
  2. Developing and assessing cardiovascular biomarkers. Transl Res. 2012 Apr; 159(4):265-76.
    View in: PubMed
    Score: 0.187
  3. Lipoprotein(a) and Risk of Incident Atherosclerotic Cardiovascular Disease: Impact of High-Sensitivity C-Reactive Protein and Risk Variability Among Human Clinical Subgroups. Nutrients. 2025 Apr 11; 17(8).
    View in: PubMed
    Score: 0.117
  4. Intensive Lifestyle Intervention, Cardiac?Biomarkers, and Cardiovascular?Outcomes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary Study. J Am Coll Cardiol. 2025 Feb 11; 85(5):489-500.
    View in: PubMed
    Score: 0.114
  5. NT-proBNP and Cardiac Troponin I, but Not Cardiac Troponin T, Are Associated With 7-Year Changes in Cardiac Structure and Function in Older Adults: The ARIC Study. Circulation. 2024 Dec 03; 150(23):1847-1857.
    View in: PubMed
    Score: 0.113
  6. Lipoprotein(a) and Progression of Coronary Artery Calcification in a Pooled?U.S. Cohort. JACC Cardiovasc Imaging. 2024 Oct; 17(10):1265-1267.
    View in: PubMed
    Score: 0.112
  7. Associations of Ambulatory Blood Pressure Measurements With High-Sensitivity Troponin and Natriuretic Peptide Levels in SPRINT. Am J Hypertens. 2024 07 15; 37(8):571-579.
    View in: PubMed
    Score: 0.111
  8. High-Sensitivity Troponin T, NT-proBNP, and Cognitive Outcomes in SPRINT. Hypertension. 2024 Sep; 81(9):1956-1965.
    View in: PubMed
    Score: 0.111
  9. Prognostic Value of Cardiovascular Biomarkers in the Population. JAMA. 2024 06 11; 331(22):1898-1909.
    View in: PubMed
    Score: 0.110
  10. Individual and Joint Associations of High-Sensitivity Troponin I and High-Sensitivity Troponin T with Cardiac Phenotypes and Outcomes in the General Population: An Analysis From the Dallas Heart Study. J Am Heart Assoc. 2024 Jul 02; 13(13):e034549.
    View in: PubMed
    Score: 0.110
  11. Atrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1. JAMA Cardiol. 2024 Jun 01; 9(6):497-506.
    View in: PubMed
    Score: 0.110
  12. High-Sensitivity Cardiac Troponins I and T and Cardiovascular Outcomes: Findings from the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Chem. 2024 02 07; 70(2):414-424.
    View in: PubMed
    Score: 0.108
  13. Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2023 11 09; 30(16):1731-1740.
    View in: PubMed
    Score: 0.106
  14. Statins and inflammatory markers. Curr Atheroscler Rep. 2002 Jan; 4(1):42-7.
    View in: PubMed
    Score: 0.093
  15. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. Clin Chem. 2021 01 08; 67(1):143-153.
    View in: PubMed
    Score: 0.087
  16. New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation. Annu Rev Med. 2021 01 27; 72:431-446.
    View in: PubMed
    Score: 0.086
  17. Levels and Change in Galectin-3 and Association With Cardiovascular Events: The ARIC Study. J Am Heart Assoc. 2020 07 07; 9(13):e015405.
    View in: PubMed
    Score: 0.084
  18. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020 04; 27(6):593-603.
    View in: PubMed
    Score: 0.079
  19. High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study. Circulation. 2019 06 04; 139(23):2642-2653.
    View in: PubMed
    Score: 0.077
  20. Sleep apnea and galectin-3: possible sex-specific relationship. Sleep Breath. 2019 Dec; 23(4):1107-1114.
    View in: PubMed
    Score: 0.076
  21. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
    View in: PubMed
    Score: 0.076
  22. Poststatin Lipid Therapeutics: A Review. Methodist Debakey Cardiovasc J. 2019 Jan-Mar; 15(1):32-38.
    View in: PubMed
    Score: 0.076
  23. Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism. J Thromb Haemost. 2018 10; 16(10):1964-1972.
    View in: PubMed
    Score: 0.074
  24. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018 10; 277:195-203.
    View in: PubMed
    Score: 0.073
  25. Plasma Galectin-3 and Sonographic Measures of Carotid Atherosclerosis in the Atherosclerosis Risk in Communities Study. Angiology. 2019 Jan; 70(1):47-55.
    View in: PubMed
    Score: 0.073
  26. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e004652.
    View in: PubMed
    Score: 0.072
  27. Short-Term Global Cardiovascular Disease Risk?Prediction in Older Adults. J Am Coll Cardiol. 2018 06 05; 71(22):2527-2536.
    View in: PubMed
    Score: 0.072
  28. Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC). Atherosclerosis. 2018 01; 268:12-18.
    View in: PubMed
    Score: 0.070
  29. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes Endocrinol. 2017 07; 5(7):534-543.
    View in: PubMed
    Score: 0.068
  30. The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. Atherosclerosis. 2017 07; 262:131-137.
    View in: PubMed
    Score: 0.068
  31. Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. Curr Cardiol Rep. 2017 03; 19(3):19.
    View in: PubMed
    Score: 0.067
  32. Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. Atherosclerosis. 2016 10; 253:156-163.
    View in: PubMed
    Score: 0.064
  33. Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death. JAMA Cardiol. 2016 08 01; 1(5):519-28.
    View in: PubMed
    Score: 0.064
  34. Determinants of minimal elevation in high-sensitivity cardiac troponin T in the general population. Clin Biochem. 2016 Jun; 49(9):657-662.
    View in: PubMed
    Score: 0.062
  35. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. Clin Cardiol. 2016 Mar; 39(3):137-44.
    View in: PubMed
    Score: 0.062
  36. Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study. Nephrol Dial Transplant. 2015 Jan; 30(1):77-83.
    View in: PubMed
    Score: 0.056
  37. Large multiethnic Candidate Gene Study for C-reactive protein levels: identification of a novel association at CD36 in African Americans. Hum Genet. 2014 Aug; 133(8):985-95.
    View in: PubMed
    Score: 0.054
  38. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014 May; 34(5):1069-77.
    View in: PubMed
    Score: 0.054
  39. Troponin T, NT-proBNP, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Vasc Med. 2014 Feb; 19(1):33-41.
    View in: PubMed
    Score: 0.054
  40. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis. 2014 Jan; 232(1):86-93.
    View in: PubMed
    Score: 0.053
  41. Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study. Circ Heart Fail. 2013 Sep 01; 6(5):936-43.
    View in: PubMed
    Score: 0.052
  42. Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study. Stroke. 2013 Jul; 44(7):1803-8.
    View in: PubMed
    Score: 0.051
  43. Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. Stroke. 2013 Apr; 44(4):961-7.
    View in: PubMed
    Score: 0.051
  44. Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players. Atherosclerosis. 2012 Jun; 222(2):551-6.
    View in: PubMed
    Score: 0.047
  45. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011 Sep-Oct; 5(5):338-67.
    View in: PubMed
    Score: 0.046
  46. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis. 2011 Dec; 219(2):737-42.
    View in: PubMed
    Score: 0.045
  47. Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study. Atherosclerosis. 2011 Dec; 219(2):596-602.
    View in: PubMed
    Score: 0.045
  48. Peripheral artery disease, biomarkers, and darapladib. Am Heart J. 2011 May; 161(5):972-8.
    View in: PubMed
    Score: 0.044
  49. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011 Apr 05; 123(13):1367-76.
    View in: PubMed
    Score: 0.044
  50. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol. 2011 May; 8(5):253-65.
    View in: PubMed
    Score: 0.044
  51. CD11c expression in adipose tissue and blood and its role in diet-induced obesity. Arterioscler Thromb Vasc Biol. 2010 Feb; 30(2):186-92.
    View in: PubMed
    Score: 0.040
  52. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009 May 05; 119(17):2408-16.
    View in: PubMed
    Score: 0.039
  53. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem. 2009 Feb; 55(2):378-84.
    View in: PubMed
    Score: 0.038
  54. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009 Feb; 40(2):376-81.
    View in: PubMed
    Score: 0.038
  55. Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study. Tex Heart Inst J. 2008; 35(4):388-94.
    View in: PubMed
    Score: 0.035
  56. How to identify patients with vulnerable plaques. Diabetes Obes Metab. 2008 Sep; 10(10):824-33.
    View in: PubMed
    Score: 0.035
  57. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005 Nov 28; 165(21):2479-84.
    View in: PubMed
    Score: 0.031
  58. Natriuretic Peptide Cut Points for Heart Failure Classification in Individuals With and Without Obesity. Circ Heart Fail. 2025 Oct; 18(10):e013112.
    View in: PubMed
    Score: 0.030
  59. Adipokines and Transitions in Metabolic Health Over Time: The Atherosclerosis Risk In Communities (ARIC) Study. J Clin Endocrinol Metab. 2025 Aug 07; 110(9):e2939-e2945.
    View in: PubMed
    Score: 0.030
  60. Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. Clin Chem. 2005 Jul; 51(7):1102-9.
    View in: PubMed
    Score: 0.030
  61. Linking Chronic Kidney Disease to Incident Heart Failure and Adverse Cardiac Remodeling Through the Plasma Proteome: The ARIC Study. JACC Heart Fail. 2025 Aug; 13(8):102512.
    View in: PubMed
    Score: 0.030
  62. Differential Associations of Cardiac, Pulmonary, Arterial, and Muscle Physiological Parameters and Biomarkers With the Incidence of HFpEF and HFrEF. JACC Heart Fail. 2025 Aug; 13(8):102483.
    View in: PubMed
    Score: 0.030
  63. A Meta-Analysis and Systematic Review of Cardiac Troponin I vs T in Community Dwelling Adults: Is Specificity at Risk? Clin Chem. 2025 Jun 03; 71(6):664-676.
    View in: PubMed
    Score: 0.030
  64. Lipoprotein(a) and Heart Failure Among Black and White Participants in Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and Multi-Ethnic Study of Atherosclerosis: The Pooling Project. J Am Heart Assoc. 2025 Jun 03; 14(11):e038608.
    View in: PubMed
    Score: 0.029
  65. The Brussels International Declaration on Lipoprotein(a) Testing and Management. Atherosclerosis. 2025 07; 406:119218.
    View in: PubMed
    Score: 0.029
  66. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis. 2005 Dec; 183(2):301-7.
    View in: PubMed
    Score: 0.029
  67. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025 Mar 04; 14(5):e038656.
    View in: PubMed
    Score: 0.029
  68. Mid-life anti-inflammatory metabolites are inversely associated with long-term cardiovascular disease events. EBioMedicine. 2025 Feb; 112:105551.
    View in: PubMed
    Score: 0.029
  69. PLAC test for identification of individuals at increased risk for coronary heart disease. Expert Rev Mol Diagn. 2005 Jan; 5(1):9-14.
    View in: PubMed
    Score: 0.029
  70. Intensive Blood Pressure Lowering in Individuals With Low Diastolic Blood Pressure and Elevated Troponin Levels in SPRINT. J Am Heart Assoc. 2024 Mar 19; 13(6):e032493.
    View in: PubMed
    Score: 0.027
  71. Galectin-3, Metabolic Risk, and Incident Heart Failure: The ARIC Study. J Am Heart Assoc. 2024 Mar 19; 13(6):e031607.
    View in: PubMed
    Score: 0.027
  72. Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2024 02 06; 83(5):562-573.
    View in: PubMed
    Score: 0.027
  73. Large-Scale Proteomics Identifies Novel Biomarkers and Circulating Risk Factors for Aortic Stenosis. J Am Coll Cardiol. 2024 02 06; 83(5):577-591.
    View in: PubMed
    Score: 0.027
  74. Age-Related Differences in the Contribution of Systolic Blood Pressure and Biomarkers to Cardiovascular Disease Risk Prediction: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Cardiol. 2023 10 01; 204:295-301.
    View in: PubMed
    Score: 0.026
  75. Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life. Sci Transl Med. 2023 07 19; 15(705):eadf5681.
    View in: PubMed
    Score: 0.026
  76. Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study. Circ Heart Fail. 2023 05; 16(5):e009694.
    View in: PubMed
    Score: 0.026
  77. Association of Long-term Change in N-Terminal Pro-B-Type Natriuretic Peptide With Incident Heart Failure and Death. JAMA Cardiol. 2023 03 01; 8(3):222-230.
    View in: PubMed
    Score: 0.025
  78. Reclassification of Pre-Heart Failure Stages Using Cardiac Biomarkers: The ARIC Study. JACC Heart Fail. 2023 04; 11(4):440-450.
    View in: PubMed
    Score: 0.025
  79. Effect of Intensive Blood Pressure Control on Troponin and Natriuretic Peptide Levels: Findings From SPRINT. Circulation. 2023 Jan 24; 147(4):310-323.
    View in: PubMed
    Score: 0.025
  80. Importance of NT-proBNP and conventional risk factors for prediction of death in older adults with and without diabetes mellitus- A report from the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Res Clin Pract. 2022 Dec; 194:110164.
    View in: PubMed
    Score: 0.025
  81. Intensive Blood Pressure Lowering in?Patients With Malignant Left?Ventricular?Hypertrophy. J Am Coll Cardiol. 2022 10 18; 80(16):1516-1525.
    View in: PubMed
    Score: 0.025
  82. Diabetes Duration and Subclinical Myocardial Injury: The Atherosclerosis Risk in Communities Study (ARIC). Clin Chem. 2022 10 06; 68(10):1272-1280.
    View in: PubMed
    Score: 0.025
  83. Soluble adhesion molecules and the search for biomarkers for atherosclerosis. Circulation. 2002 Aug 13; 106(7):766-7.
    View in: PubMed
    Score: 0.024
  84. Growth Differentiation Factor 15 and the Subsequent Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. Clin Chem. 2022 07 27; 68(8):1084-1093.
    View in: PubMed
    Score: 0.024
  85. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1?, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation. 2022 08 02; 146(5):372-379.
    View in: PubMed
    Score: 0.024
  86. Longitudinal Changes in Cardiac Troponin and Risk of Heart Failure Among Black Adults. J Card Fail. 2023 01; 29(1):6-15.
    View in: PubMed
    Score: 0.024
  87. Sex and Race Differences in N-Terminal Pro-B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the Community. JAMA Cardiol. 2022 06 01; 7(6):623-631.
    View in: PubMed
    Score: 0.024
  88. A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. Sci Transl Med. 2022 04 06; 14(639):eabj9625.
    View in: PubMed
    Score: 0.024
  89. Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study. Diabetologia. 2022 06; 65(6):955-963.
    View in: PubMed
    Score: 0.024
  90. Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Serious Adverse Events in SPRINT. J Am Heart Assoc. 2022 03 15; 11(6):e023314.
    View in: PubMed
    Score: 0.024
  91. NT-pro B-type natriuretic peptide, early menopause, and incident heart failure in postmenopausal women of the ARIC study. Menopause. 2022 01 14; 29(3):309-316.
    View in: PubMed
    Score: 0.023
  92. Proteomics and Risk of Atrial Fibrillation in Older Adults (From the Atherosclerosis Risk in Communities [ARIC] Study). Am J Cardiol. 2021 12 15; 161:42-50.
    View in: PubMed
    Score: 0.023
  93. Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering: Findings From the SPRINT Randomized Clinical Trial. JAMA Cardiol. 2021 12 01; 6(12):1397-1405.
    View in: PubMed
    Score: 0.023
  94. The Fifth-Generation Cardiac Troponin T and Cardiovascular Disease in the Community. J Am Coll Cardiol. 2021 11 16; 78(20):2019-2021.
    View in: PubMed
    Score: 0.023
  95. Identification of Functional Genetic Determinants of Cardiac Troponin T and I in a Multiethnic Population and Causal Associations With Atrial Fibrillation. Circ Genom Precis Med. 2021 12; 14(6):e003460.
    View in: PubMed
    Score: 0.023
  96. Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. J Clin Lipidol. 2021 Sep-Oct; 15(5):629-648.
    View in: PubMed
    Score: 0.023
  97. Association of Longitudinal Changes in Cardiac Biomarkers With Atrial and Ventricular Arrhythmias (from the Atherosclerosis Risk in Communities [ARIC] Study). Am J Cardiol. 2021 11 01; 158:45-52.
    View in: PubMed
    Score: 0.023
  98. What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. J Am Heart Assoc. 2021 08 17; 10(16):e020893.
    View in: PubMed
    Score: 0.023
  99. Upper Reference Limits for High-Sensitivity Cardiac Troponin T and N-Terminal Fragment of the Prohormone Brain Natriuretic Peptide in Patients With CKD. Am J Kidney Dis. 2022 Mar; 79(3):383-392.
    View in: PubMed
    Score: 0.023
  100. Six-year changes in N-terminal pro-brain natriuretic peptide and changes in weight and risk of obesity. Obesity (Silver Spring). 2021 07; 29(7):1215-1222.
    View in: PubMed
    Score: 0.022
  101. Growth Differentiation Factor (GDF)-15 and Cardiometabolic Outcomes among Older Adults: The Atherosclerosis Risk in Communities Study. Clin Chem. 2021 03 31; 67(4):653-661.
    View in: PubMed
    Score: 0.022
  102. Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study. J Am Coll Cardiol. 2021 02 09; 77(5):559-571.
    View in: PubMed
    Score: 0.022
  103. Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2021 05 01; 146:15-21.
    View in: PubMed
    Score: 0.022
  104. High-Sensitivity Cardiac Troponin, Natriuretic Peptide, and Long-Term Risk of Acute Kidney Injury: The Atherosclerosis Risk in Communities (ARIC) Study. Clin Chem. 2021 01 08; 67(1):298-307.
    View in: PubMed
    Score: 0.022
  105. Biomarker-Based Risk Prediction of Incident Heart?Failure in Pre-Diabetes and?Diabetes. JACC Heart Fail. 2021 03; 9(3):215-223.
    View in: PubMed
    Score: 0.022
  106. High-sensitivity cardiac troponin T and the risk of heart failure in postmenopausal women of the ARIC Study. Menopause. 2021 01 04; 28(3):284-291.
    View in: PubMed
    Score: 0.022
  107. High-Sensitivity Cardiac Troponin I for Risk Stratification in Older Adults. J Am Geriatr Soc. 2021 04; 69(4):986-994.
    View in: PubMed
    Score: 0.021
  108. High-Sensitivity Cardiac Troponin I and T for Cardiovascular Risk Stratification in Adults With Diabetes. Diabetes Care. 2020 10; 43(10):e144-e146.
    View in: PubMed
    Score: 0.021
  109. Combining Biomarkers and Imaging for Short-Term Assessment of Cardiovascular Disease Risk in Apparently Healthy Adults. J Am Heart Assoc. 2020 08 04; 9(15):e015410.
    View in: PubMed
    Score: 0.021
  110. Fibrosis and Inflammatory Markers and Long-Term Risk of Peripheral Artery Disease: The ARIC Study. Arterioscler Thromb Vasc Biol. 2020 09; 40(9):2322-2331.
    View in: PubMed
    Score: 0.021
  111. Development and assessment of antiatherosclerotic therapies beyond low-density lipoprotein cholesterol and blood pressure. Curr Atheroscler Rep. 2000 Jul; 2(4):281-3.
    View in: PubMed
    Score: 0.021
  112. Associations of Cardiac, Kidney, and Diabetes Biomarkers With Peripheral Neuropathy among Older Adults in the Atherosclerosis Risk in Communities (ARIC) Study. Clin Chem. 2020 05 01; 66(5):686-696.
    View in: PubMed
    Score: 0.021
  113. Performance of High-Sensitivity Cardiac Troponin Assays to Reflect Comorbidity Burden and Improve Mortality Risk Stratification in Older Adults With Diabetes. Diabetes Care. 2020 06; 43(6):1200-1208.
    View in: PubMed
    Score: 0.021
  114. Cardiac Biomarkers and Subsequent Risk of Hospitalization With Bleeding in the Community: Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2020 03 03; 9(5):e013560.
    View in: PubMed
    Score: 0.021
  115. Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. JAMA. 2020 Jan 28; 323(4):329-338.
    View in: PubMed
    Score: 0.020
  116. Cancer Survivorship and Subclinical Myocardial Damage. Am J Epidemiol. 2019 12 31; 188(12):2188-2195.
    View in: PubMed
    Score: 0.020
  117. Associations of High-Sensitivity Cardiac Troponin and Natriuretic Peptide With Subsequent Risk of Infection in Persons Without Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2019 12 31; 188(12):2146-2155.
    View in: PubMed
    Score: 0.020
  118. Relationship of extracellular volume assessed on cardiac magnetic resonance and serum cardiac troponins and natriuretic peptides with heart failure outcomes. Sci Rep. 2019 12 27; 9(1):20168.
    View in: PubMed
    Score: 0.020
  119. Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. Circulation. 2019 12 17; 140(25):2076-2088.
    View in: PubMed
    Score: 0.020
  120. Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. JAMA Cardiol. 2019 10 01; 4(10):997-1006.
    View in: PubMed
    Score: 0.020
  121. Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17?180 Individuals. Circ Res. 2019 09 27; 125(8):773-782.
    View in: PubMed
    Score: 0.020
  122. Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018?AHA/ACC Cholesterol Guidelines. J Am Coll Cardiol. 2019 08 06; 74(5):712-714.
    View in: PubMed
    Score: 0.020
  123. High-Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change. J Am Geriatr Soc. 2019 11; 67(11):2353-2361.
    View in: PubMed
    Score: 0.020
  124. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. Postgrad Med. 2019 Aug; 131(6):390-396.
    View in: PubMed
    Score: 0.020
  125. Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction. Am Heart J. 2019 10; 216:62-73.
    View in: PubMed
    Score: 0.020
  126. Subclinical Cardiovascular Disease and Fall Risk in Older Adults: Results From the Atherosclerosis Risk in Communities Study. J Am Geriatr Soc. 2019 09; 67(9):1795-1802.
    View in: PubMed
    Score: 0.020
  127. ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change. Neurology. 2019 05 28; 92(22):e2580-e2593.
    View in: PubMed
    Score: 0.019
  128. Relation of Isolated Systolic Hypertension and Pulse Pressure to High-Sensitivity Cardiac Troponin-T and N-Terminal pro-B-Type Natriuretic Peptide in Older Adults (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2019 07 15; 124(2):245-252.
    View in: PubMed
    Score: 0.019
  129. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation. 2019 03 05; 139(10):1341-1343.
    View in: PubMed
    Score: 0.019
  130. Central and peripheral pulse wave velocity and subclinical myocardial stress and damage in older adults. PLoS One. 2019; 14(2):e0212892.
    View in: PubMed
    Score: 0.019
  131. Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004817.
    View in: PubMed
    Score: 0.019
  132. Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. Am J Hum Genet. 2018 11 01; 103(5):691-706.
    View in: PubMed
    Score: 0.019
  133. Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2018 07; 274:86-93.
    View in: PubMed
    Score: 0.018
  134. Usefulness of Lipoprotein-Associated Phospholipase A2 Activity and C-Reactive Protein in Identifying High-Risk Smokers for Atherosclerotic Cardiovascular Disease (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2018 05 01; 121(9):1056-1064.
    View in: PubMed
    Score: 0.018
  135. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol. 2018 02 01; 3(2):164-168.
    View in: PubMed
    Score: 0.018
  136. Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure: ARIC Study. Circulation. 2018 05 15; 137(20):2142-2151.
    View in: PubMed
    Score: 0.018
  137. Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. J Am Heart Assoc. 2017 Dec 15; 6(12).
    View in: PubMed
    Score: 0.018
  138. SES, Heart Failure, and N-terminal Pro-b-type Natriuretic Peptide: The Atherosclerosis Risk in Communities Study. Am J Prev Med. 2018 02; 54(2):229-236.
    View in: PubMed
    Score: 0.018
  139. Lipoprotein(a) and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study. Atherosclerosis. 2018 01; 268:63-67.
    View in: PubMed
    Score: 0.018
  140. Relation of Lifestyle Factors and Life's Simple 7 Score to Temporal Reduction in Troponin Levels Measured by a High-Sensitivity Assay (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2018 02 15; 121(4):430-436.
    View in: PubMed
    Score: 0.018
  141. Midlife Systemic Inflammation, Late-Life White Matter Integrity, and Cerebral Small Vessel Disease: The Atherosclerosis Risk in Communities Study. Stroke. 2017 12; 48(12):3196-3202.
    View in: PubMed
    Score: 0.017
  142. Sedentary Behavior and Subclinical Cardiac Injury: Results From the Dallas Heart Study. Circulation. 2017 10 10; 136(15):1451-1453.
    View in: PubMed
    Score: 0.017
  143. Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. Kidney Int. 2018 01; 93(1):252-259.
    View in: PubMed
    Score: 0.017
  144. Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2017 Oct; 192:19-25.
    View in: PubMed
    Score: 0.017
  145. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. Atherosclerosis. 2017 Aug; 263:137-144.
    View in: PubMed
    Score: 0.017
  146. Physical Activity, Obesity, and Subclinical?Myocardial Damage. JACC Heart Fail. 2017 05; 5(5):377-384.
    View in: PubMed
    Score: 0.017
  147. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis. 2017 06; 261:12-18.
    View in: PubMed
    Score: 0.017
  148. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. JAMA Cardiol. 2017 04 01; 2(4):361-369.
    View in: PubMed
    Score: 0.017
  149. Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts. Circulation. 2017 05 30; 135(22):2119-2132.
    View in: PubMed
    Score: 0.017
  150. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. Int J Cardiol. 2017 Apr 15; 233:61-66.
    View in: PubMed
    Score: 0.017
  151. Myocardial Injury, Obesity, and the Obesity Paradox: The ARIC Study. JACC Heart Fail. 2017 01; 5(1):56-63.
    View in: PubMed
    Score: 0.016
  152. High-Sensitivity Cardiac Troponin T (hs-cTnT) as a Predictor of Incident Diabetes in the Atherosclerosis Risk in Communities Study. Diabetes Care. 2017 Feb; 40(2):261-269.
    View in: PubMed
    Score: 0.016
  153. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes Endocrinol. 2016 10; 4(10):840-9.
    View in: PubMed
    Score: 0.016
  154. Alcohol Consumption and Cardiac Biomarkers: The Atherosclerosis Risk in Communities (ARIC) Study. Clin Chem. 2016 09; 62(9):1202-10.
    View in: PubMed
    Score: 0.016
  155. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016 Apr 19; 315(15):1580-90.
    View in: PubMed
    Score: 0.016
  156. Influence of cigarette smoking on cardiac biomarkers: the Atherosclerosis Risk in Communities (ARIC) Study. Eur J Heart Fail. 2016 06; 18(6):629-37.
    View in: PubMed
    Score: 0.016
  157. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circ Cardiovasc Genet. 2016 Jun; 9(3):240-9.
    View in: PubMed
    Score: 0.016
  158. The Association of Socioeconomic Status With Subclinical Myocardial Damage, Incident Cardiovascular Events, and Mortality in the ARIC Study. Am J Epidemiol. 2016 Mar 01; 183(5):452-61.
    View in: PubMed
    Score: 0.015
  159. N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2016 Feb 16; 133(7):631-8.
    View in: PubMed
    Score: 0.015
  160. Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2016 May; 39(5):677-85.
    View in: PubMed
    Score: 0.015
  161. Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. Atherosclerosis. 2016 Mar; 246:115-20.
    View in: PubMed
    Score: 0.015
  162. Prognostic Significance of High-Sensitivity Cardiac Troponin T Concentrations between the Limit of Blank and Limit of Detection in Community-Dwelling Adults: A Metaanalysis. Clin Chem. 2015 Dec; 61(12):1524-31.
    View in: PubMed
    Score: 0.015
  163. Severity of hypoxia modulates effect of CPAP on myocardial stress as measured by highly sensitive troponin T. Respir Res. 2015 Oct 16; 16:126.
    View in: PubMed
    Score: 0.015
  164. Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort: The Atherosclerosis Risk in Communities-Sleep Heart Health Study. Circulation. 2015 Oct 06; 132(14):1329-37.
    View in: PubMed
    Score: 0.015
  165. Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study. Am Heart J. 2015 Nov; 170(5):961-7.
    View in: PubMed
    Score: 0.015
  166. High-Sensitivity Cardiac Troponin T and Risk of Hypertension. Circulation. 2015 Sep 01; 132(9):825-33.
    View in: PubMed
    Score: 0.015
  167. Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015 Aug 18; 132(7):578-85.
    View in: PubMed
    Score: 0.015
  168. Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. Metab Syndr Relat Disord. 2015 Aug; 13(6):239-47.
    View in: PubMed
    Score: 0.015
  169. Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. Am Heart J. 2015 Aug; 170(2):380-9.
    View in: PubMed
    Score: 0.015
  170. Patterns and determinants of temporal change in high-sensitivity cardiac troponin-T: The Atherosclerosis Risk in Communities Cohort Study. Int J Cardiol. 2015; 187:651-7.
    View in: PubMed
    Score: 0.015
  171. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial. Atherosclerosis. 2015 Jun; 240(2):490-6.
    View in: PubMed
    Score: 0.015
  172. The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. J Hepatol. 2015 Apr; 62(4):841-7.
    View in: PubMed
    Score: 0.014
  173. sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Diabetes Complications. 2015 Mar; 29(2):180-5.
    View in: PubMed
    Score: 0.014
  174. FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. JACC Cardiovasc Imaging. 2015 Apr; 8(4):493-494.
    View in: PubMed
    Score: 0.014
  175. High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities study. Hypertension. 2015 Jan; 65(1):78-84.
    View in: PubMed
    Score: 0.014
  176. Association of high-sensitivity cardiac troponin T and natriuretic peptide with incident ESRD: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis. 2015 Apr; 65(4):550-8.
    View in: PubMed
    Score: 0.014
  177. Obesity, subclinical myocardial injury, and incident heart failure. JACC Heart Fail. 2014 Dec; 2(6):600-7.
    View in: PubMed
    Score: 0.014
  178. Association of body mass index and waist circumference with subclinical atherosclerosis in retired NFL players. South Med J. 2014 Oct; 107(10):633-9.
    View in: PubMed
    Score: 0.014
  179. Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. Atherosclerosis. 2014 Oct; 236(2):251-6.
    View in: PubMed
    Score: 0.014
  180. B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace. 2014 Oct; 16(10):1426-33.
    View in: PubMed
    Score: 0.014
  181. Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study. Arterioscler Thromb Vasc Biol. 2014 Aug; 34(8):1770-7.
    View in: PubMed
    Score: 0.014
  182. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia. Atherosclerosis. 2014 Jun; 234(2):249-53.
    View in: PubMed
    Score: 0.014
  183. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol. 2014 Apr 15; 63(14):1441-8.
    View in: PubMed
    Score: 0.013
  184. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014 Apr; 15(4):380-8.
    View in: PubMed
    Score: 0.013
  185. The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. J Obes. 2013; 2013:729515.
    View in: PubMed
    Score: 0.013
  186. Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. Am J Respir Crit Care Med. 2013 Dec 15; 188(12):1460-5.
    View in: PubMed
    Score: 0.013
  187. The editor's roundtable: hypertriglyceridemia. Am J Cardiol. 2013 Oct 15; 112(8):1133-41.
    View in: PubMed
    Score: 0.013
  188. Elevated high-sensitivity C-reactive protein as a risk marker of the attenuated relationship between serum cholesterol and cardiovascular events at older age. The ARIC Study. Am J Epidemiol. 2013 Oct 01; 178(7):1076-84.
    View in: PubMed
    Score: 0.013
  189. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013 Jul 09; 12:100.
    View in: PubMed
    Score: 0.013
  190. The association of plasma lactate with incident cardiovascular outcomes: the ARIC Study. Am J Epidemiol. 2013 Aug 01; 178(3):401-9.
    View in: PubMed
    Score: 0.013
  191. Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. Med Sci Sports Exerc. 2013 Jun; 45(6):1043-50.
    View in: PubMed
    Score: 0.013
  192. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes. 2013 Jun; 62(6):2116-21.
    View in: PubMed
    Score: 0.013
  193. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013 Feb; 13(1):37-46.
    View in: PubMed
    Score: 0.013
  194. Combined association of creatinine, albuminuria, and cystatin C with all-cause mortality and cardiovascular and kidney outcomes. Clin J Am Soc Nephrol. 2013 Mar; 8(3):434-42.
    View in: PubMed
    Score: 0.012
  195. Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. Ann Epidemiol. 2013 Feb; 23(2):66-73.
    View in: PubMed
    Score: 0.012
  196. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29; 367(22):2089-99.
    View in: PubMed
    Score: 0.012
  197. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis. 2012 May; 59(5):653-62.
    View in: PubMed
    Score: 0.012
  198. Chronic hyperglycemia and subclinical myocardial injury. J Am Coll Cardiol. 2012 Jan 31; 59(5):484-9.
    View in: PubMed
    Score: 0.012
  199. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol. 2012 Feb; 5(1):155-62.
    View in: PubMed
    Score: 0.012
  200. Programmable bio-nanochip technology for the diagnosis of cardiovascular disease at the point-of-care. Methodist Debakey Cardiovasc J. 2012 Jan; 8(1):6-12.
    View in: PubMed
    Score: 0.012
  201. Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study. Clin Chem. 2011 Jun; 57(6):891-7.
    View in: PubMed
    Score: 0.011
  202. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. Arterioscler Thromb Vasc Biol. 2011 Jul; 31(7):1689-95.
    View in: PubMed
    Score: 0.011
  203. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation. 2011 Feb 22; 123(7):731-8.
    View in: PubMed
    Score: 0.011
  204. Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study. Arterioscler Thromb Vasc Biol. 2010 May; 30(5):1034-42.
    View in: PubMed
    Score: 0.010
  205. Using the whole cohort in the analysis of case-cohort data. Am J Epidemiol. 2009 Jun 01; 169(11):1398-405.
    View in: PubMed
    Score: 0.010
  206. Association of lactate with blood pressure before and after rapid weight loss. Am J Hypertens. 2008 Dec; 21(12):1337-42.
    View in: PubMed
    Score: 0.009
  207. Expression, activation, and function of integrin alphaMbeta2 (Mac-1) on neutrophil-derived microparticles. Blood. 2008 Sep 15; 112(6):2327-35.
    View in: PubMed
    Score: 0.009
  208. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008 Apr 29; 51(17):1632-41.
    View in: PubMed
    Score: 0.009
  209. Glutamic acid decarboxylase antibodies are indicators of the course, but not of the onset, of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities Study. Braz J Med Biol Res. 2007 Jul; 40(7):933-41.
    View in: PubMed
    Score: 0.009
  210. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006 Jul 10; 166(13):1368-73.
    View in: PubMed
    Score: 0.008
  211. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006 Mar; 259(3):247-58.
    View in: PubMed
    Score: 0.008
  212. P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the Atherosclerosis Risk in Communities Study. Atherosclerosis. 2006 May; 186(1):74-9.
    View in: PubMed
    Score: 0.007
  213. B vitamin status and inflammatory markers. Atherosclerosis. 2003 Jul; 169(1):169-74.
    View in: PubMed
    Score: 0.006
  214. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997 Dec 16; 96(12):4219-25.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.